Cytek Biosciences, Inc.: Form 10-Q for the period ended Mar 31, 2023
Filed with the SEC on May 9, 2023 and accepted by EDGAR at May 9, 2023, 16:38 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-01-01 to 2023-03-31 | $37.1m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2023-01-01 to 2023-03-31 | $16.1m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2023-01-01 to 2023-03-31 | $21.0m | us-gaap:GrossProfit |
| Research and development | 3 months2023-01-01 to 2023-03-31 | $10.0m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2023-01-01 to 2023-03-31 | −$12.2m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2023-01-01 to 2023-03-31 | $673.0k | us-gaap:InterestExpense |
| Income tax | 3 months2023-01-01 to 2023-03-31 | −$2.2m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-01-01 to 2023-03-31 | −$6.8m | us-gaap:NetIncomeLoss |
| Diluted shares (weighted) | 3 months2023-01-01 to 2023-03-31 | 135,489,194 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2023-01-01 to 2023-03-31 | $2.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2023-01-01 to 2023-03-31 | $505.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2023-03-31 | $129.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-03-31 | $425.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-03-31 | $524.6m | us-gaap:Assets |
| Current liabilities | At period end2023-03-31 | $56.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-03-31 | $101.1m | us-gaap:Liabilities |
| Shareholders' equity | At period end2023-03-31 | $423.5m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-23-019777. Last ingested by Listed: Nov 3, 2026, 22:13 ET. Listed shows no prices and gives no investment advice.